^
    Back
    Association details:
    Biomarker:HER-2 I655V
    Cancer:Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.

    Published date:
    05/13/2020
    Excerpt:
    Logistic regression analysis adjusted by hormonal status and anthracycline treatment showed higher cardiotoxicity risk for AG vs AA Her2-Ile655 polimorphism (OR = 3.00, CI95% 1.07-8.41, p = 0.037) or for AG vs AA+GG Her2-Ile655 polimorphism (OR = 3.21, CI95% 1.15-8.96, p = 0.026).
    DOI:
    10.1200/JCO.2020.38.15_suppl.1033
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer

    Published date:
    06/01/2014
    Excerpt:
     In contrast, among the 212 patients who received adjuvant trastuzumab treatment, we found that patients with the Val/Ile or the Val/Val genotype had a significantly better 5-year DFS and 5-year DDFS than did those with the Ile/Ile genotype (5-year DFS, 100% versus 83%; P = 0.008; 5-year DDFS, 100% versus 89%; P = 0.031)
    DOI:
    10.1093/annonc/mdu111